Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Kina vs Voxy

Kina
Graded #118

Higher grade

vs+7.699999999999996
Voxy
Graded #280

Lower grade

The verdict

Kina takes it — 69.8/100 to 62.1/100.

Kina grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Kina is a menopause-care telehealth platform where GLP-1 is the weight-loss treatment, offered alongside HRT, peptide, and compounded options for menopause symptoms.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueKina +10
60
50
Dose & formulationEven
64
64
Clinical oversightKina +6
88
82
Labs & monitoringKina +1
64
63
FulfillmentKina +5
83
78
Contract termsKina +41
61
20
Kina · left barVoxy · right bar

The numbers

MetricKinaVoxy
WeighScore69.8/10062.1/100
GradeCC
Scorecard rank#118#280
Semaglutide$179/mo (starting dose, plus a separate fee, compounded)$179/mo (compounded)
Tirzepatide$179/mo (starting dose, compounded)$299/mo (compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Kina

Graded #118 · C

Strengths

  • Menopause-specialized care — GLP-1 weight treatment alongside HRT, peptide, and compounded options for menopause symptoms
  • Prescribed and monitored by named board-certified physicians at Arora Health & Aesthetics, with dose adjustments included
  • Verifiable LegitScript certification (seal ID 50917967)
  • GLP-1 from $179/month with $0 membership fees, FSA/HSA eligibility, free shipping, and cancel-anytime
  • Compounded semaglutide and tirzepatide, 100% online with a roughly 2-minute intake

Where it loses points

  • Compounded medications are not FDA-approved — not brand Wegovy, Ozempic, Zepbound, or Mounjaro
  • Built for women navigating menopause — less tailored if that is not your situation
  • A separate $50 physician consultation fee applies on top of the medication price
  • The compounding pharmacy partner is not named, and the full list of served states is not published
Voxy

Graded #280 · C

Strengths

  • Names both its compounding pharmacy (VialsRX, Houston TX) and its prescribing medical group (Arora Health & Aesthetics) — most name neither
  • Publishes the full price ladder for both drugs across 1-, 3-, 6- and 12-month terms before you start the assessment
  • One price covers the provider visit, medication, injection supplies, shipping and monthly check-ins — no separate membership fee
  • True month-to-month option at $179 semaglutide / $299 tirzepatide with no commitment required
  • Free assessment with no charge to see if you qualify, and no labs required to start

Where it loses points

  • No terms of service anywhere on the site — /terms, /terms-of-service and /terms-of-use all return 404
  • No refund policy published; the only stated commitment language is 'cancel anytime'
  • Advertised 'Starting at $129/mo' is the 12-month prepay rate — month-to-month is $179 semaglutide and $299 tirzepatide
  • No public list of states served; availability depends on where affiliated providers are licensed
  • The prescribing nurse practitioner is not named — 'provider details available during your consultation'

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard